2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
March 28, 2018
Xenon Pharmaceuticals Confirms Closing of Transaction with Teva and Announces Preferred Share Exchange Agreement with BVF Partners L.P.
BURNABY, British Columbia, March 28, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today reported the closing of the previously announced transaction with Teva Pharmaceuticals International GmbH, along with Teva Canada Limited (colle... More >>
March 13, 2018
Dr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief Medical Officer
Changes to Senior Leadership Support Expanding Neurology Pipeline BURNABY, British Columbia, March 13, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that Dr. Ernesto Aycardi will join the company as its Chief Medical... More >>
March 7, 2018
Xenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate Update
Two novel anti-epileptic drugs advancing in clinical development; Interim XEN1101 Phase 1 data expected to be released in May 2018 at scientific symposium; Xenon announces new clinical stage ion channel product to expand its neurology pipeline BURNABY, British Columbia, March 07, 2018 (GLOBE ... More >>
February 28, 2018
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2017 Financial Results and Provide Corporate Update
BURNABY, British Columbia, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2017 financial and operating results after the close of U.S. financial markets on Wednesday, March 7, 2018.  Xe... More >>
February 20, 2018
Xenon Pharmaceuticals Advances Second Proprietary Epilepsy Product into the Clinic with Initiation of XEN901 Phase 1 Clinical Trial
BURNABY, British Columbia, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced the initiation of a Phase 1 clinical trial of its proprietary epilepsy product candidate, XEN901, which is an orally administered, smal... More >>
January 8, 2018
Xenon Pharmaceuticals Outlines Key Milestones for 2018
BURNABY, British Columbia, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today provided a corporate update and outlined its anticipated key corporate milestones for 2018. Dr. Simon Pimstone, Xenon's President and Chief Ex... More >>